Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.57 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243100 | 0.85 | SIGMAR1 (0.78) | SIGMAR1 | |
| SCHEMBL7243865 | 0.84 | SIGMAR1 (0.50) | SIGMAR1 | |
| SCHEMBL7242535 | 0.83 | SIGMAR1 (0.52) | SIGMAR1GRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL7242631 | 0.79 | SIGMAR1 (0.54) | SIGMAR1 | |
| SCHEMBL7243612 | 0.79 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL7247975 | 0.76 | OPRM1 (0.48) | SIGMAR1GRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL7242441 | 0.75 | CHRM1 (0.51) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7250528 | 0.74 | CHRM1 (0.50) | SIGMAR1 | |
| SCHEMBL7243054 | 0.73 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL7248520 | 0.73 | SIGMAR1 (0.49) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CELLTECH R & D LIMITED (GB) | 2003-09-11 | — | — | US | claimed |
| EP-1311502-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Celltech R&D Limited (GB) | 2003-05-21 | — | — | EP | claimed |
| WO-2002016353-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CELLTECH R & D LIMITED (GB) | 2002-02-28 | — | — | WO | claimed |
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CELLTECH R & D LIMITED (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CCR1, CCR3, CCRL2 | SIGMAR1 325/4885GRIN2D 1925/4885GRIN3B 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.